The U.S. District Court for the District of Delaware ruled that Actavis' generic version of opioid-addiction medicine Zubsolv infringed on Orexo AB's patent.
The court's decision stops Actavis from marketing its Zubsolv generic products in all dosage strengths in the U.S. until after Sept. 18, 2032.
Zubsolv is a mixture of buprenorphine and naloxone, which are commonly used to treat narcotic addiction.
A Sept. 10, 2018, decision by the U.S. Court of Appeals for the Federal Circuit previously reinforced the validity of Orexo's patent, reversing a November 2016 ruling by the U.S. District Court for the District of Delaware saying that Orexo's Zubsolv patent was invalid.
Sweden-based Orexo said it has withdrawn other Zubsolv patent cases against Actavis as a result of the final judgment. Meanwhile, the company noted that the court's decision is not related to Orexo's patent infringement case against Actavis involving generic versions of opioid dependence medicines, Suboxone and Subutex tablets.
Actavis was acquired by Allergan PLC in March 2015 and renamed it as Allergan Inc. two months after. Actavis was purchased by Teva Pharmaceutical Industries Ltd. in August 2016.